Scholarlink

<p>A small proportion of cutaneous squamous cell carcinomas (CSCC) belongs to the group of advanced tumors that require adjuvant radiotherapy in addition to surgical resection. Despite the combination of these treatment modalities recurrences and distant metastases are not uncommon and are difficult to treat. The immuno-oncological medicament cemiplimab (monoclonal antibody against programmed cell death 1 protein, PD‑1 receptor) has been approved for a long time for the treatment in an unresectable situation (advanced or metastatic CSCC). The central objective of the C‑POST trial was to assess the effectiveness and safety of cemiplimab as adjuvant therapy in comparison to placebo in patients with resected high-risk CSCC after conclusion of postoperative radiotherapy. The results led to approval of cemiplimab in Germany for this group of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Zulassung von Cemiplimab für die adjuvante Therapie bei Patienten mit kutanem Plattenepithelkarzinom mit Risikofaktoren – die C-POST-Studie

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Urs D. A. Müller-Richter

摘要

A small proportion of cutaneous squamous cell carcinomas (CSCC) belongs to the group of advanced tumors that require adjuvant radiotherapy in addition to surgical resection. Despite the combination of these treatment modalities recurrences and distant metastases are not uncommon and are difficult to treat. The immuno-oncological medicament cemiplimab (monoclonal antibody against programmed cell death 1 protein, PD‑1 receptor) has been approved for a long time for the treatment in an unresectable situation (advanced or metastatic CSCC). The central objective of the C‑POST trial was to assess the effectiveness and safety of cemiplimab as adjuvant therapy in comparison to placebo in patients with resected high-risk CSCC after conclusion of postoperative radiotherapy. The results led to approval of cemiplimab in Germany for this group of patients.